Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Prostate Cancer and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4808
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Prostate Cancer and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Prostate Cancer and Antibodies.

    To find out more about Triple Analysis: Lymphoma, Prostate Cancer and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Prostate Cancer and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Alfacell
Algeta
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amorfix Life Sciences
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardana
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Berkeley Lab
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
Biolex
BioLineRx
BioMarin
BioNetWorks
BioSante
Biosceptre
Biostar
Biotecnol
Biotest
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Camurus
Cancer Innovations
Cancer Research Technology
Cel-Sci
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
Chemokine Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
Cornerstone Pharmaceuticals
Cosmo Bioscience
CSL
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
DiaMedica
Dompe
Dongkook Pharm
Dr Reddy’s
Dyax
Dynavax Technologies
ECI
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Enzon
EpiCept
Epizyme
Ergon Pharmaceuticals
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
Ferring
FibroGen
Five Prime Therapeutics
Forma Therapeutics
Formula Pharmaceuticals
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GENova Biotherapeutics
Genovax
GenPat77
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hawthorn Pharmaceuticals
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IDM Pharma
IGF Oncology
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Ivy Medical Chemicals
Johnson & Johnson
Kaketsuken
KaloBios
Karo Bio
Kinex
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
Molecular Insight
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
Neurocrine Biosciences
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
Noxxon
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaGap
PharmaMar
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Q Chip
QLT
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
SBI Biotech
SBIO
Scancell
Seattle Genetics
SeleXel
Selvita
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shire
Siena Biotech
Soligenix
Sophiris Bio
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Tau Therapeutics
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
Tokai Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxon Biotech
Velacor Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroTarg
Viventia Biotech
VM Discovery
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEZS-108
afatinib
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
ALT-801
alvocidib
amatuximab
AME-133
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
APC-100
APR-246
ARC-100
atrasentan
AV-299
AVX-701
bafetinib
belimumab
belinostat
bevacizumab
bexarotene
BHQ880
BIBF-1120
bicalutamide
blinatumomab
BMS-663513
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
brentuximab vedotin
BT-062
buserelin
Cabozantinib
carlumab
catumaxomab
CDX-1307
CDX-1401
cediranib
celecoxib
cetuximab
cixutumumab
cladribine
CMAB302
CMAB304
conatumumab
CT-011
custirsen
dalotuzumab
danusertib
daratumumab
dasatinib
DCVax-prostate
degarelix
denileukin diftitox
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
elliptinium acetate
elotuzumab
EMD-273063
EMD525797
entinostat
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
ertumaxomab
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
farletuzumab
figitumumab
flutamide
fresolimumab
fulvestrant
galiximab
ganitumab
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
goserelin
GS-6634
GTx-758
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histrelin
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
inecalcitol
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukins
intetumumab
IPH-2102
ipilimumab
iratumumab
irinotecan hydrochloride
irosustat
ispinesib mesylate
KX2-391
L19-TNFalpha
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
lintuzumab
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDV-3100
MEDI-551
MEDI-573
milatuzumab
milatuzumab-doxorubicin
mitoxantrone
MLN-8237
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
Nab-docetaxel
nadroparin
naptumomab estafenatox
natalizumab
necitumumab
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
OGX-427
olaparib
olaratumab
onartuzumab
Onyvax-105
oregovomab
orteronel
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
PAT-SC1
perifosine
pertuzumab
PF-4856884
pixantrone
plitidepsin
PLX-3397
pralatrexate
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
razoxane
Reditux
retaspimycin
RG-7160
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
robatumumab
romidepsin
romiplostim
ruxolitinib
sagopilone
samalizumab
SAR-3419
sargramostim
SB-939
siltuximab
sipuleucel-T
sobuzoxane
sorafenib tosylate
sotatercept
Sym-004
TAK-448
tandutinib
tasquinimod
temsirolimus
Tenarad
teniposide
tigatuzumab
tocilizumab
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
veltuzumab
volociximab
YM-155
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Prostate Cancer and Antibodies.
    To find out more about Triple Analysis: Lymphoma, Prostate Cancer and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Prostate Cancer and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Leukemia and Melanoma
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Melanoma. Learn More


Triple Analysis: Lymphoma, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Adherens Junction Targeting in Oncology Drug Pipeline Update
BioSeeker Group have identified 277 companies plus partners who are today developing 357 targeting adherens junctions drugs in 1199 developmental projects in cancer across 134 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More


Triple Analysis: Colorectal Cancer, Lymphoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More